Rhythm Pharmaceuticals (RYTM) Other Non Operating Income (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Other Non Operating Income data on file, last reported at -$1.7 million in Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 164.6% year-over-year to -$1.7 million in Q1 2026; TTM through Mar 2026 was $203000.0, a 90.6% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, down 43.55% from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$1.7 million, down from $57000.0 in the prior quarter.
• Over the last five years, Other Non Operating Income for RYTM reached as high as $8.4 million in Q2 2024 and fell as low as -$6.7 million in Q4 2024.
• Historically, Other Non Operating Income has averaged $111529.4 across 5 years, with a median of -$27000.0 in 2023.
• On a YoY basis, Other Non Operating Income climbed as much as 49370.59% in 2024 and fell as far as 1905.15% in 2024.
• Year by year, Other Non Operating Income stood at -$420000.0 in 2022, then jumped by 187.86% to $369000.0 in 2023, then plunged by 1905.15% to -$6.7 million in 2024, then soared by 100.86% to $57000.0 in 2025, then tumbled by 3089.47% to -$1.7 million in 2026.
• Per Business Quant data, the three most recent Other Non Operating Income figures were -$1.7 million in Q1 2026, $57000.0 in Q4 2025, and $274000.0 in Q3 2025.